Investing
Investing Cash Flow
Regeneron Pharmaceuticals Investing Cash Flow decreased by 6.5% to -$428.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 166.2%, from $647.50M to -$428.90M. Over 2 years (FY 2021 to FY 2023), Investing Cash Flow shows an upward trend with a -23.1% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
Typically negative for growing companies as they reinvest cash; a positive value suggests the company is liquidating assets faster than it is buying them.
Detailed definition
The aggregate sum of all cash inflows and outflows related to a company's long-term investments and capital assets. It s...
Peer comparison
Mature companies with high cash flow often show large negative values here as they recycle profits into new growth or financial instruments.
Metric ID:
net_cash_from_investingHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $125.80M | -$2.44B | -$2.01B | -$1.71B | -$413.90M | $192.30M | -$1.86B | -$235.70M | -$2.39B | -$496.30M | -$66.20M | -$1.69B | -$557.20M | -$574.40M | $647.50M | -$1.09B | -$402.90M | -$428.90M |
| QoQ Change | — | <-999% | +17.5% | +15.3% | +75.7% | +146.5% | <-999% | +87.3% | -912.7% | +79.2% | +86.7% | <-999% | +67.0% | -3.1% | +212.7% | -269.0% | +63.2% | -6.5% |
| YoY Change | — | — | — | — | -429.0% | +107.9% | +7.7% | +86.2% | -476.7% | -358.1% | +96.4% | -615.8% | +76.7% | -15.7% | +138.4% | -96.3% | +29.9% | -166.2% |
Range-$2.44B – $647.50M
CAGR+33.5%
Avg YoY Growth-115.3%
Median YoY Growth-4.0%
Investing Cash Flow at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's investing cash flow?
- Regeneron Pharmaceuticals (REGN) reported investing cash flow of -$428.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's investing cash flow changed year-over-year?
- Regeneron Pharmaceuticals's investing cash flow decreased by 166.2% year-over-year, from $647.50M to -$428.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's investing cash flow?
- Over 2 years (2021 to 2023), Regeneron Pharmaceuticals's investing cash flow has grown at a -23.1% compound annual growth rate (CAGR), from -$5.38B to -$3.19B.
- What does investing cash flow mean?
- The total net change in cash resulting from buying and selling long-term assets and investments.